X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/29/2871603/0/en/Pediatric-Brain-Tumor-Foundation-celebrates-FDA-approval-of-Day-One-Biopharmaceuticals-OJEMDA-new-treatment-for-common-pediatric-brain-tumor-type.html
https://www.globenewswire.com/news-release/2024/04/25/2869527/7281/en/XOMA-Earns-9-Million-Milestone-as-FDA-Grants-Accelerated-Approval-to-Day-One-s-OJEMDATM-tovorafenib-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric#:~:text=On%20April%2023%2C%202024%2C%20the,rearrangement%2C%20or%20BRAF%20V600%20mutation.
https://www.globenewswire.com/news-release/2024/04/23/2868089/0/en/Day-One-s-OJEMDA-tovorafenib-Receives-US-FDA-Accelerated-Approval-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG-the-Most-Common-Form-of-Childhood-Brain-Tu.html
https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated
https://www.globenewswire.com//news-release/2023/10/31/2770043/7281/en/XOMA-Earns-5-Million-Milestone-Upon-FDA-Acceptance-of-Day-One-s-Tovorafenib-NDA-for-Relapsed-or-Progressive-Pediatric-Low-Grade-Glioma-pLGG.html
https://www.globenewswire.com//news-release/2023/10/30/2769134/0/en/Day-One-Announces-FDA-Acceptance-of-NDA-and-Priority-Review-for-Tovorafenib-in-Relapsed-or-Progressive-Pediatric-Low-Grade-Glioma-pLGG.html
https://www.globenewswire.com//news-release/2023/09/12/2741236/0/en/Day-One-Announces-Updated-FIREFLY-1-Data-for-Tovorafenib-and-Completion-of-Rolling-NDA-Submission-to-FDA-for-Relapsed-or-Progressive-Pediatric-Low-Grade-Glioma-pLGG.html
https://www.globenewswire.com/news-release/2023/05/26/2676824/0/en/CORRECTION-Day-One-Announces-Tovorafenib-DAY101-Data-and-Additional-Abstracts-to-be-Presented-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
https://www.fiercebiotech.com/biotech/good-day-day-one-pediatric-brain-tumor-drug-proves-worth-phase-2
https://www.globenewswire.com/news-release/2023/01/08/2584748/0/en/Day-One-Announces-Topline-Data-from-Pivotal-Phase-2-FIREFLY-1-Trial-Demonstrating-Meaningful-Responses-with-Tovorafenib-DAY101-in-Recurrent-or-Progressive-Pediatric-Low-Grade-Gliom.html
https://www.globenewswire.com/news-release/2022/10/17/2535426/0/en/Day-One-Announces-Cooperative-Research-and-Development-Agreement-with-National-Cancer-Institute-to-Expand-Development-of-Tovorafenib-DAY101.html
https://www.globenewswire.com/news-release/2022/10/17/2535408/0/en/Fennec-Pharmaceuticals-Announces-Commercial-Availability-of-PEDMARK-sodium-thiosulfate-injection-in-the-United-States.html
Market Place
Share 
